Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000469:Alkaline Phosphatase / Q000378:metabolism; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D019540:Area Under Curve; D018450:Disease Progression; D004791:Enzyme Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D061965:Matrix Metalloproteinase Inhibitors; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009930:Organic Chemicals / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D013997:Time Factors
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D061965:Matrix Metalloproteinase Inhibitors; D009930:Organic Chemicals; C113282:prinomastat; D000469:Alkaline Phosphatase